Central Nervous System (CNS) Lymphoma: Symptoms, Causes, Diagnosis, and Treatment
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: September 2026
Editorial note: This article is for general education only and is not a substitute for professional medical advice. It draws exclusively on published clinical sources. Always consult a qualified healthcare professional for diagnosis and treatment decisions.
Quick Answer
CNS lymphoma is a rare form of non-Hodgkin lymphoma that develops in the brain, spinal cord, or surrounding fluid, and occasionally in the eyes. It causes about 1,500 new U.S. cases per year and most often affects adults in their 60s and 70s. The two forms are primary (starting in the nervous system) and secondary (spreading from elsewhere). Treatment relies mainly on chemotherapy that can cross the blood-brain barrier, sometimes with radiation, stem cell transplant, or CAR-T therapy. Outcomes vary widely by age and immune status.
CNS lymphoma is cancer of the immune cells (lymphocytes) in the brain, spinal cord, or fluid around them. It is rare — roughly 1,500 U.S. cases per year — and most often strikes adults over 60. Symptoms mimic other brain conditions: persistent headaches, memory and personality changes, weakness, seizures, and vision problems. A biopsy is usually required to confirm it, because imaging alone cannot distinguish it from gliomas, metastases, or infections. The main treatment is methotrexate-based chemotherapy, with radiation, stem cell transplant, and CAR-T reserved for select cases. It is more common in people with weakened immune systems (HIV/AIDS, transplant medications), and the Epstein-Barr virus is a known risk factor.
What is central nervous system (CNS) lymphoma?
Central nervous system (CNS) lymphoma is a type of lymphoma — cancer of the lymphatic system — that affects the brain, the spinal cord, and the fluid that surrounds them. It can also affect the eyes. Unlike most brain tumors, it does not start in brain cells. It starts in immune cells called lymphocytes, which normally fight infection. In CNS lymphoma, these cells grow out of control and form one or more tumors, sometimes called masses.
Most CNS lymphomas are non-Hodgkin lymphomas. This disease is a serious and potentially life-threatening illness, but there are treatment options. The outcome depends on overall health, how much of the central nervous system is involved, and how well treatment destroys the cancer.
CNS lymphoma accounts for only about 1% to 2% of all non-Hodgkin lymphomas and roughly 3% to 4% of newly diagnosed central nervous system tumors. In the United States, approximately 1,500 new cases are diagnosed each year, and it represents about 4% of all brain tumors.
Key facts at a glance
What it is: non-Hodgkin lymphoma of lymphocytes in the brain, spinal cord, fluid, or eyes
U.S. cases per year: approximately 1,500 (about 4% of brain tumors)
Incidence rate: roughly 0.4 to 0.5 per 100,000 people per year
Peak age: most often diagnosed in the 60s and 70s
Most common subtype: diffuse large B-cell lymphoma (~90% of primary cases)
Share of non-Hodgkin lymphomas: about 1% to 2%
How common is CNS lymphoma, and who gets it?
CNS lymphoma is rare. The incidence rate in the United States is about 0.4 to 0.5 cases per 100,000 people per year, based on national registry data. For comparison, all primary brain and central nervous system tumors combined occur at a rate of 26.05 per 100,000.
Age is the strongest demographic factor. It occurs most often in people in their 60s and 70s. The incidence rate in people aged 70 to 79 is about 4.32 per 100,000 — roughly 50 times higher than the 0.08 per 100,000 seen in people aged 20 to 29. The median age at diagnosis is around 65 in people with normal immune systems, compared with 40 to 49 in AIDS-associated cases.
Men are diagnosed slightly more often than women. U.S. data show an incidence of 0.55 per 100,000 in men versus 0.39 per 100,000 in women, a ratio of about 1.1 to 1.
Immune status matters enormously. CNS lymphoma is more likely when the immune system is weakened — by HIV/AIDS, by medications used after organ transplantation, or by congenital immunodeficiency. It is considered an AIDS-defining illness.
What are the two types of CNS lymphoma?
CNS lymphoma is classified by where it started.
Primary CNS lymphoma (PCNSL) starts in the central nervous system itself — the brain, the spinal cord, the fluid that surrounds them, and sometimes the eyes. Most primary cases are diffuse large B-cell lymphomas, beginning in lymphocytes called B cells. Because this cancer affects areas that control thinking, movement, and vision, symptoms often include changes in how the brain works. About 90% of primary cases are diffuse large B-cell lymphoma, and most cases involve a single brain lesion; roughly 87% are located above the tentorium (supratentorial), with 39% in the frontoparietal lobes.
Secondary CNS lymphoma (SCNSL) begins in another part of the body, such as the lymph nodes or other organs, and later spreads to the brain, the spinal cord, or the fluid around them. It can also spread to the eyes. Some aggressive types of systemic lymphoma are more likely to reach the central nervous system.
Primary (PCNSL): starts in brain, spinal cord, fluid, or eyes; ~90% are diffuse large B-cell lymphoma; often a single brain lesion; median age ~65 (immunocompetent)
Secondary (SCNSL): starts in lymph nodes or organs elsewhere; reflects the subtype of the original lymphoma; multiple systemic sites usually involved; median age 40–49 when HIV-associated
What are the symptoms of CNS lymphoma?
Symptoms vary from person to person and often depend on where the cancer is located within the central nervous system. Some symptoms develop gradually, while others appear suddenly or worsen quickly.
The most common symptoms include persistent or worsening headaches, nausea and vomiting, changes in thinking, memory or concentration, personality or behavior changes, weakness or numbness in part of the body, trouble with balance or walking, seizures, and vision problems such as blurred vision. Less common symptoms — ataxia, vertigo, nerve pain, and even bladder or bowel dysfunction — can appear when specific brain areas are affected.
Head pressure: headaches that don't go away or get worse over time; nausea; vomiting
Thinking and behavior: memory loss, poor concentration, personality changes
Movement: weakness or numbness on one side; balance and walking trouble
Seizures: new seizure activity in an adult
Vision: blurred vision, floaters, decreased acuity (eye involvement)
Because these symptoms overlap with stroke, dementia, infections, and other brain tumors, CNS lymphoma is frequently mistaken for something else early on. That is why imaging and biopsy are both needed.
What causes CNS lymphoma?
The exact cause of CNS lymphoma is not known. It happens when changes occur in certain immune cells called lymphocytes, causing them to grow out of control and form cancer. Researchers do not know why lymphoma develops in the central nervous system in some people, but the disease may be linked to changes in the immune system that affect how lymphocytes grow and function.
About 90% of primary cases are diffuse large B-cell lymphomas. The abnormal B cells amplify growth pathways such as NF-κB and may silence tumor suppressor genes. It is unclear whether normal lymphocytes transform into cancer inside the CNS or whether already-malignant lymphocytes migrate into the brain.
What are the risk factors for CNS lymphoma?
Three risk factors stand out in the medical literature: older age, a weakened immune system, and Epstein-Barr virus (EBV) infection.
Older age: primary CNS lymphoma is more common in older adults. It occurs most often in people in their 60s and 70s. Incidence in people over 60 has been rising by roughly 1.6% to 1.7% per year over recent decades.
A weakened immune system: CNS lymphoma is more likely when immunity is impaired. This includes people taking medications to suppress the immune system after an organ transplant, people living with HIV/AIDS, and people with congenital immunodeficiency syndromes. Notably, the share of CNS lymphoma cases linked to HIV has fallen sharply — from about 64% in the early 1990s to roughly 13% by 2011 — as antiretroviral therapy has improved.
Epstein-Barr virus (EBV): EBV infection is linked to CNS lymphoma, especially in people with weakened immune systems.
Other reported risk factors include male sex, autoimmune diseases such as lupus and Sjögren syndrome, and having an aggressive type of lymphoma elsewhere in the body, which can spread to the CNS.
Older age — most often diagnosed in 60s–70s; rate rises ~1.6–1.7%/yr over 60
Immunosuppression — transplant medications, HIV/AIDS, congenital immunodeficiency
HIV/AIDS — AIDS-defining illness; share of cases fell from 64% to ~13% (1992–2011)
Epstein-Barr virus — strongly linked in immunocompromised patients
Male sex — slightly higher incidence (1.1:1 male-to-female)
Aggressive systemic lymphoma — higher chance of spreading to the CNS
What complications can CNS lymphoma cause?
CNS lymphoma and its treatment can cause complications during or after treatment. These vary by patient.
Increased pressure in the brain — tumors or swelling can raise pressure inside the skull, leading to worsening headaches, nausea, vomiting, or changes in alertness
Lasting problems with movement, speech, or vision — damage to the brain, spinal cord, or eyes can cause ongoing changes, even after treatment ends
Infections — some treatments weaken the immune system, increasing infection risk
Changes in memory or thinking — some treatments, especially whole-brain radiation, can alter thinking, memory, or focus, either short term or long term
Not everyone with CNS lymphoma experiences these complications. Healthcare teams monitor for problems and help manage them when they occur.
How is CNS lymphoma diagnosed?
Diagnosing CNS lymphoma often involves several steps. On scans, it can look like other brain conditions — including gliomas, brain metastases, and infections. In people with weakened immune systems, toxoplasmosis can cause brain lesions that look similar to CNS lymphoma. Because of this, several tests are usually needed to confirm the diagnosis.
Neurological exam — tests vision, balance, coordination, strength, reflexes, and thinking skills
Imaging tests — MRI is usually preferred, done with and without contrast when possible; sometimes CT is used instead; additional imaging checks for lymphoma elsewhere in the body
Biopsy — removes a small piece of tissue for lab analysis; usually needed to confirm the diagnosis; stereotactic (needle-guided) biopsy is preferred over surgical removal
Spinal fluid tests — a lumbar puncture (spinal tap) collects cerebrospinal fluid, tested for cancer cells
Eye exam — if there are eye symptoms, a slit-lamp exam with a microscope and bright light checks for lymphoma
On MRI or CT, CNS lymphoma usually appears as a spot that brightens after contrast ("enhancement"), sometimes with a brighter outer edge called ring enhancement. These findings suggest lymphoma but cannot confirm it alone.
One important clinical note: corticosteroids are cytotoxic to lymphoma cells. Giving them before a biopsy can shrink or dissolve the lesions, produce ambiguous imaging, and delay diagnosis. Guidelines therefore recommend avoiding steroids during the diagnostic workup unless swelling becomes dangerous.
How is CNS lymphoma staged?
Many cancers use stages 1 through 4, but CNS lymphoma is often described differently. Healthcare professionals focus on where the lymphoma is found and whether it is limited to the nervous system or involves other body parts. The care team uses tests to learn the location (brain, spinal cord, fluid, eyes), whether it started in the CNS or spread there, and how far it has spread within the CNS. In some cases, the Ann Arbor staging system is used, and primary CNS lymphoma may be described as stage 1E — lymphoma in one area outside the lymph nodes.
How is CNS lymphoma treated?
Treatment usually begins with chemotherapy. Other options include immunotherapy, targeted therapy, corticosteroids, radiation therapy, and CAR-T cell therapy. High-dose chemotherapy followed by a bone marrow (stem cell) transplant is sometimes used. The choice depends on the type of CNS lymphoma, overall health, age, and how much of the central nervous system is involved. The goals are to control the cancer, ease symptoms, and protect brain function.
Chemotherapy — high-dose drugs that cross the blood-brain barrier; methotrexate-based regimens are the first-line mainstay, since systemic lymphoma drugs often cannot reach the brain
Radiation therapy — precise energy beams targeting the tumor, used alone or after chemotherapy; can affect memory and thinking
Stem cell transplant — replaces blood-forming cells after high-dose chemotherapy; used after a good initial response or at relapse
Immunotherapy / targeted therapy — helps the immune system recognize or blocks the signals cancer cells need to grow; used with chemo, or at relapse/refractoriness
Corticosteroids — reduces brain swelling for symptom relief; often delayed until after biopsy since they can shrink tumors and blur diagnosis
CAR-T cell therapy — engineered T cells hunt cancer cells; an option for refractory or relapsed primary disease
Antiretroviral therapy — treats underlying HIV, improving immune function and outcomes in HIV-related CNS lymphoma
Surgery generally plays a limited role: it is used to obtain biopsy samples, but surgical removal of the tumor itself does not improve outcomes in CNS lymphoma.
What is the outlook (prognosis) for CNS lymphoma?
Without treatment, CNS lymphoma progresses quickly — untreated overall survival is roughly 1.5 months. With modern treatment, overall survival is approximately 2 to 5 years, and some patients achieve long-term remission.
Prognosis depends heavily on age and risk factors. The IELSG risk-scoring system estimates 2-year survival at about 80% for 0 to 1 risk factors, 48% for 2 to 3 risk factors, and 15% for 4 to 5 risk factors. The five IELSG risk factors are age over 60, reduced performance status, elevated lactate dehydrogenase, elevated cerebrospinal fluid protein, and deep brain involvement.
Overall 5-year survival is commonly reported in the range of roughly 27% to 38%, with lower rates in people over 70 and in those with HIV. Factors associated with poorer outcomes include age over 60, HIV-positive status, elevated LDH, high CSF protein, nonhemispheric brain involvement, and intraocular disease combined with brain involvement.
When should you see a doctor?
Persistent headaches that worsen over time, unexplained personality or memory changes, new seizures, weakness on one side of the body, or new vision problems — especially in someone over 60 or with a weakened immune system — warrant prompt medical evaluation. These symptoms often mimic more common conditions, but a timely neurological exam and brain imaging are the fastest way to rule serious causes in or out.
Seek emergency care immediately for a new seizure, sudden loss of consciousness, rapid-onset weakness on one side, or signs of dangerous pressure inside the skull such as repeated vomiting with confusion or reduced alertness.
What does living with CNS lymphoma look like?
A CNS lymphoma diagnosis is a lot to process. Give yourself time to understand the condition and the treatments available. Ask your care team questions and take notes on important details.
Family and friends can provide support during treatment, and talking with others who have cancer can bring comfort. If you feel overwhelmed, ask your care team to connect you with counselors or social workers.
Because appointments can be brief, preparing ahead helps: list symptoms and when they began, note major stresses or recent health changes, bring a complete medication list (including over-the-counter drugs and supplements), bring copies of scans or test results, and consider bringing a family member or friend who can help remember what was discussed.
The bottom line
CNS lymphoma is a rare but treatable cancer of the immune cells in the brain, spinal cord, and surrounding fluid. It strikes most often in adults over 60 and is strongly tied to immune-system changes. A biopsy is usually required to confirm it, and modern treatment — centered on chemotherapy that can reach the brain, with radiation, transplant, and CAR-T options — gives many patients meaningful survival gains. If you or a loved one has persistent neurological symptoms, the single most important step is to see a doctor promptly for evaluation.
If you have unexplained headaches, memory changes, seizures, or vision problems — especially with a weakened immune system — don't wait. Talk to a healthcare professional and ask whether brain imaging is appropriate. Early diagnosis gives treatment the best possible chance.
Frequently asked questions
Is CNS lymphoma a brain tumor?
CNS lymphoma forms in the brain and spinal cord, but unlike most brain tumors it starts in immune cells (lymphocytes), not in brain tissue. It is classified as a lymphoma — specifically a type of non-Hodgkin lymphoma — and is treated quite differently from gliomas and other brain cancers.
Is primary CNS lymphoma curable?
Complete, lasting remission is possible but uncommon. Many patients achieve remission with methotrexate-based chemotherapy, and some remain disease-free for years, but the cancer frequently relapses. With treatment, overall survival is roughly 2 to 5 years, and outcomes vary widely by age and immune status.
What is the most common type of primary CNS lymphoma?
About 90% of primary CNS lymphomas are diffuse large B-cell lymphomas, which begin in B-cell lymphocytes. Less common types include Burkitt, low-grade B-cell, and T-cell lymphomas.
Is CNS lymphoma caused by HIV?
HIV does not directly cause CNS lymphoma, but a weakened immune system from HIV/AIDS raises the risk substantially, and CNS lymphoma is considered an AIDS-defining illness. The EBV virus — which is more active when immunity is low — is also linked. Improved HIV treatment has sharply reduced the HIV share of cases.
Can CNS lymphoma spread to the eyes?
Yes. Both primary and secondary CNS lymphoma can involve the eyes. When eye symptoms occur, a full exam by an eye specialist — often including a slit-lamp exam — is part of the diagnostic workup.
How long can you live with CNS lymphoma?
Untreated, survival is roughly 1.5 months. With modern treatment, overall survival averages about 2 to 5 years, and patients with fewer IELSG risk factors can see 2-year survival of 80%. Younger, fitter patients who tolerate intensive therapy tend to do best.
Is surgery an option for CNS lymphoma?
Surgery's role is limited to biopsy. Removing the tumor does not improve outcomes because the disease diffusely infiltrates brain tissue and responds to chemotherapy. The mainstay of treatment is methotrexate-based chemotherapy.
Does radiation to the brain cause memory problems in CNS lymphoma patients?
Brain radiation can affect memory and thinking, so clinicians carefully weigh benefits and risks before recommending it. Alternatives such as high-dose chemotherapy with stem cell transplant are often considered, particularly in older patients.
References
Central nervous system (CNS) lymphoma — Symptoms & causes. Mayo Clinic, medically reviewed, updated April 01, 2026. mayoclinic.org/diseases-conditions/central-nervous-system-lymphoma/symptoms-causes/syc-20598772
Central nervous system (CNS) lymphoma — Diagnosis & treatment. Mayo Clinic, medically reviewed, updated April 01, 2026. mayoclinic.org/diseases-conditions/central-nervous-system-lymphoma/diagnosis-treatment/drc-20598773
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018–2022. Neuro-Oncology, 2025. academic.oup.com/neuro-oncology/article/26/Supplement_6/vi1/7797290
Primary Central Nervous System Lymphoma (PCNSL) Epidemiology. Rare Disease Advisor, referencing SEER and CBTRUS studies. rarediseaseadvisor.com/disease-info-pages/primary-central-nervous-system-lymphoma-epidemiology/
CBTRUS Fact Sheet 2025. Central Brain Tumor Registry of the United States (2018–2022 U.S. data). cbtrus.org/cbtrus-fact-sheet/
CNS Lymphoma. Cancer Therapy Advisor, updated January 28, 2026. cancertherapyadvisor.com/ddi/cns-lymphoma/
Primary central nervous system lymphoma in the United States, 1975–2017. Lv C, et al. Therapeutic Advances in Hematology, 2022. pmc.ncbi.nlm.nih.gov/articles/PMC8793121/
CNS Lymphoma. StatPearls Publishing (NCBI Bookshelf). ncbi.nlm.nih.gov/books/NBK563302/
Primary Central Nervous System Lymphoma. American Brain Tumor Association. abta.org/tumor_types/primary-central-nervous-system-lymphoma
CNS Lymphoma (Primary) — Symptoms, Prognosis, Diagnosis. Cancer Therapy Advisor, updated January 28, 2026. cancertherapyadvisor.com/ddi/cns-lymphoma/
Comments